Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Cited In for PubMed (Select 10622296)

1.

Regulatory decisions pertaining to aprotinin may be putting patients at risk.

Hébert PC, Fergusson DA, Hutton B, Mazer CD, Fremes S, Blajchman M, MacAdams C, Wells G, Robblee J, Bussières J, Teoh K; BART Investigators.

CMAJ. 2014 Dec 9;186(18):1379-86. doi: 10.1503/cmaj.131582. Epub 2014 Sep 29. No abstract available.

PMID:
25267766
2.
3.

Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.

Kumar Y, Vadivel K, Schmidt AE, Ogueli GI, Ponnuraj SM, Rannulu N, Loo JA, Bajaj MS, Bajaj SP.

Biochemistry. 2014 Jan 28;53(3):505-17. doi: 10.1021/bi401584b. Epub 2014 Jan 13.

4.

Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults.

Wademan BH, Galvin SD.

Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):360-70. doi: 10.1093/icvts/ivt491. Epub 2013 Nov 21. Review.

5.

Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.

Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M.

Clin Pharmacol Ther. 2013 Apr;93(4):326-34. doi: 10.1038/clpt.2012.249. Epub 2012 Dec 24.

6.

Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.

Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A.

BMJ. 2012 Sep 11;345:e5798. doi: 10.1136/bmj.e5798. Review.

7.

Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis.

Ker K, Edwards P, Perel P, Shakur H, Roberts I.

BMJ. 2012 May 17;344:e3054. doi: 10.1136/bmj.e3054. Review.

8.

Preanesthetic Assessment of the Jehovah's Witness Patient.

Lin ES, Kaye AD, Baluch AR.

Ochsner J. 2012 Spring;12(1):61-9.

9.

Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era.

DeSantis SM, Toole JM, Kratz JM, Uber WE, Wheat MJ, Stroud MR, Ikonomidis JS, Spinale FG.

Circulation. 2011 Sep 13;124(11 Suppl):S62-9. doi: 10.1161/CIRCULATIONAHA.110.002543.

10.

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K.

Cochrane Database Syst Rev. 2011 Mar 16;(3):CD001886. doi: 10.1002/14651858.CD001886.pub4. Review.

11.

Transfusion-free anesthetic management for open heart surgery in a neonate -A case report-.

Lee JM, Byon HJ, Kim JT, Kim HS, Kim CS.

Korean J Anesthesiol. 2010 Dec;59 Suppl:S141-5. doi: 10.4097/kjae.2010.59.S.S141. Epub 2010 Dec 31.

12.

Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party.

Blood Transfus. 2011 Jan;9(1):19-40. doi: 10.2450/2010.0074-10. No abstract available.

13.

Management of bleeding following major trauma: an updated European guideline.

Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR; Task Force for Advanced Bleeding Care in Trauma.

Crit Care. 2010;14(2):R52. doi: 10.1186/cc8943. Epub 2010 Apr 6.

14.

No effect of a homoeopathic combination of Arnica montana and Bryonia alba on bleeding, inflammation, and ischaemia after aortic valve surgery.

Cornu C, Joseph P, Gaillard S, Bauer C, Vedrinne C, Bissery A, Melot G, Bossard N, Belon P, Lehot JJ.

Br J Clin Pharmacol. 2010 Feb;69(2):136-42. doi: 10.1111/j.1365-2125.2009.03574.x.

15.

Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study.

Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA.

Br J Anaesth. 2009 Jun;102(6):785-92. doi: 10.1093/bja/aep089. Epub 2009 May 2.

16.
17.

Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model.

McEvoy MD, Sabbagh MJ, Taylor AG, Zavadzkas JA, Koval CN, Stroud RE, Ford RL, McLean JE, Reeves ST, Mukherjee R, Spinale FG.

Anesth Analg. 2009 Feb;108(2):399-406. doi: 10.1213/ane.0b013e31818cdb13.

18.

Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I.

Sabbagh MJ, Looper JM, Zavadzkas JA, Stroud RE, Ford RL, Rivers WT, Koval CN, McEvoy MD, Reeves ST, Spinale FG.

J Cardiovasc Pharmacol. 2008 Oct;52(4):355-62. doi: 10.1097/FJC.0b013e3181893659.

19.

Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion.

McEvoy MD, Taylor AG, Zavadzkas JA, Mains IM, Ford RL, Stroud RE, Jeffords LB, Beck CU, Reeves ST, Spinale FG.

Ann Thorac Surg. 2008 Aug;86(2):568-75. doi: 10.1016/j.athoracsur.2008.04.025.

20.

Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass.

Dorman BH, Stroud RE, Wyckoff MM, Zellner JL, Botta D, Leonardi AH, Ikonomidis JS, Spinale FG.

J Cardiovasc Pharmacol. 2008 Apr;51(4):418-23. doi: 10.1097/FJC.0b013e318168400a.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk